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Abstract
Dilated cardiomyopathy (DCM), characterized by left ventricular dilatation and systolic dysfunction, constitutes a significant
cause for heart failure, sudden cardiac death or need for heart transplantation. Lamin A/C gene (LMNA) on chromosome
1p12 is the most significant disease gene causing DCM and has been reported to cause 7–9% of DCM leading to cardiac
transplantation. We have previously performed cardiac magnetic resonance imaging (MRI) to LMNA carriers to describe the
early phenotype. Clinically, early recognition of subjects at risk of developing DCM would be important but is often difficult.
Thus we have earlier used the MRI findings of these LMNA carriers for creating a model by which LMNA carriers could be
identified from the controls at an asymptomatic stage. Some LMNA mutations may cause lipodystrophy. To characterize
possible effects of LMNA mutations on lipid profile, we set out to apply global serum lipidomics using Ultra Performance
Liquid Chromatography coupled to mass spectrometry in the same LMNA carriers, DCM patients without LMNA mutation
and controls. All DCM patients, with or without LMNA mutation, differed from controls in regard to distinct serum lipidomic
profile dominated by diminished odd-chain triglycerides and lipid ratios related to desaturation. Furthermore, we introduce
a novel approach to identify associations between the molecular lipids from serum and the MR images from the LMNA
carriers. The association analysis using dependency network and regression approaches also helped us to obtain novel
insights into how the affected lipids might relate to cardiac shape and volume changes. Our study provides a framework for
linking serum derived molecular markers not only with clinical endpoints, but also with the more subtle intermediate
phenotypes, as derived from medical imaging, of potential pathophysiological relevance.
Citation: Sysi-Aho M, Koikkalainen J, Seppa¨nen-Laakso T, Kaartinen M, Kuusisto J, et al. (2011) Serum Lipidomics Meets Cardiac Magnetic Resonance Imaging:
Profiling of Subjects at Risk of Dilated Cardiomyopathy. PLoS ONE 6(1): e15744. doi:10.1371/journal.pone.0015744
Editor: Carlo Gaetano, Istituto Dermopatico dell’Immacolata, Italy
Received September 23, 2010; Accepted November 27, 2010; Published January 20, 2011
Copyright:  2011 Sysi-Aho et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors were supported by grants from the Finnish Foundation for Cardiovascular Research (TH), Finnish Medical Foundation (TH), the special
governmental subsidy for health sciences research TYH 7106 and TYH2009121 (TH), and the European Commission (ATHEROREMO project, FP7-HEALTH-2007-A
contract number 201668) to MO. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: matej.oresic@vtt.fi
Introduction
Dilated cardiomyopathy (DCM) is characterized by left
ventricular dilatation and decreased contractility. DCM consti-
tutes a significant cause for heart failure, sudden cardiac death or
need for heart transplantation. At least 25% of DCM has been
estimated to be familial [1]. The etiology, including genetic
background is heterogeneous, with most disease-causing mutations
accounting for a variable amount of DCM cases depending on the
family and pedigree. So far the sole exception to this is the lamin
A/C gene (LMNA) on chromosome 1p12 [2]. LMNA is the most
significant disease gene causing DCM [3] and has been reported to
cause up to 9% of DCM leading to heart transplantation [4].
LMNA codes both for lamin A and C proteins. A type lamins are
expressed in most differentiated cells [5]. They are structural
components of the nuclear lamina and involved in replication and
transcription. At the cellular level, the mutations may affect the
polymerization of the lamins, disrupt the structure of the nucleus
and impair the function of chromatin. Clinically, mutations of the
LMNA are associated with a large spectrum of human diseases
called laminopathies, ranging from severe dilated cardiomyopathy
to muscular dystrophy, progeria or lipodystrophy and altered
plasma lipid levels [6,7]. In women without known LMNA-
mutations, low lamin A/C expression in adipose tissue has been
reported to associate with increased fat cell lipolysis and altered
lipid profile, including lower levels of high density lipoprotein
cholesterol (HDL) [8]. The underlying disease mechanisms of
LMNA mutations are a target of intensive research.
Clinically, identifying subjects in an early phase of developing
DCM would be important but it is often difficult and for example
subtle abnormalities in echocardiography may easily be overseen.
We have previously shown that specific parameters derived from
the heart cine magnetic resonance (MR) images help identify
LMNA carriers from the controls at an early stage [9]. Here we
apply global serum lipidomics in the same LMNA carriers and
controls to examine possible effects of LMNA mutations to serum
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lipid profiles. Secondly, a novel visualization model was created to
predict the possible effects of changes in these lipid parameters to
left ventricular function as assessed by cardiac MRI.
Results
Study design
We first investigated the differences in serum lipidomes and cine
MR image data between the LMNA carriers not diagnosed with
DCM, and matched healthy controls (Figure 1). The ‘‘Lamin+’’
study included two groups: (Group 1) 11 LMNA mutation carriers
at high risk of DCM, who were at the time of analysis not
diagnosed with DCM, and (Group 2) 11 healthy controls that were
age and gender matched to Group 1. Next, we investigated which
of the molecular changes from the first study are generalized to
DCM and are thus not specifically associated with the LMNA
mutation. The second study (‘‘Lamin2‘‘ study), was performed
independently, to provide control plasma samples from LMNA-
mutation negative DCM patients for lipidomic analyses. It
included also two groups: (Group 3) 8 diagnosed DCM patients
without the LMNA mutation, and (Group 4) 8 healthy controls
that were gender matched to Group 3. Clinical summary of the
study participants is shown in Table 1.
We applied Ultra Performance Liquid Chromatography
coupled to mass spectrometry (UPLC/MSTM) to study molecular
lipids as previously described [10]. A total of 286 lipids were
identified across all four groups and included in the analysis. In
addition, we also calculated ratios of specific lipids reflecting
enzyme activities of fatty acid desaturation and elongation, which
contributed additional 267 variables. The lipid variables were then
log-transformed to make their distribution more Gaussian. In
total, the final lipidomics dataset comprised 553 variables
measured across all 38 subjects.
The cine MR images were analyzed from 11 LMNA carriers
and their 11 matched controls (Groups 1 and 2). Surface models of
the epicardium (1516 points) and the endocardium of the left and
right ventricles (906 points each) containing all together
3328 points were mapped on the heart images. The heart surface
models were also used to derive 86 variables that describe
anatomical and physiological features of the heart, as described
earlier [9].
LMNA subjects have a distinct serum lipidomic profile
A total of 57 and 56 lipid variables were found significantly
different when comparing Groups 1&2 and Groups 3&4,
respectively (Table S1). Comparison of profiles of LMNA carriers
(Group 1) and their controls (Group 2) revealed differences
dominated by several phosphatidylethanolamines, with the
direction of change depending on the fatty acid composition, as
well as by diminished odd-chain triglycerides and lipid ratios
related to desaturation (i.e., increase of double bonds). Since
LMNA mutations are known to be associated with lipid
metabolism [11], the detected differences may be specific to
LMNA mutation but may not be directly relevant to the risk of
DCM. In a follow-up study we therefore investigated subjects
diagnosed with DCM, but without LMNA mutation (Group 3),
and controls which were not matched for age (Group 4).
Comparison of the results from the two studies revealed seven
common molecular lipids which were differentially regulated in
LMNA mutation carriers as well as in subjects diagnosed with
DCM (Table 2).
In order to further investigate the disease specificity of lipidomic
changes detected in LMNA mutation carriers, we used the lipids
from Table 2 to fit a logistic regression model to samples from
Groups 1&2 with the LMNA mutation (elevated DCM risk) as the
Figure 1. Study design, methods, and outcomes.
doi:10.1371/journal.pone.0015744.g001
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response variable. The best subset of lipids was selected by the
stepwise AIC algorithm [12]. The classification threshold of the
regression model was tuned to minimize the number of
misclassifications. The final model included only one variable,
the odd-chain triglyceride TG(49:3) (Figure 2A). The same model
applied to samples from Groups 3&4 performed reasonably well
(P=0.044 by Chi-square test; Figure 2B–E), suggesting that the
marker is not due to LMNA mutation but is DCM specific.
Lipidomic profile from LMNA mutation carriers associates
with specific cardiac shape and volume changes
Next, we investigated in the group of LMNA mutation carriers
if and how are the detected lipid changes reflected in cardiac
shape and volume changes as measured by cine MR imaging.
The MRI-derived parameters were compared between the
Groups 1 and 2 and 19 variables out of 86 were found to be
different (P,0.05 by Wilcoxon test). Linear correlation analysis
between these image variables and the 57 significantly changing
lipids (Table S1) revealed a large degree of positive or negative
associations (Figure 3A), suggesting the serum lipidomic profile
does reflect the changes in the heart shape and volume of the
LMNA mutation carriers. To further study the specific
dependencies of these variables, we applied the undirected
Gaussian graphical Markov model which has been previously
applied to study gene regulatory network from small sample sets
[13] (Figure 3B). Such an approach aims at deriving the partial
correlations between two variables conditioning on the remaining
ones, and building a network where the variables are connected
by an edge if and only if their partial correlation is significantly
non-zero. Unlike the Pearson correlation coefficients, use of
partial correlation adjusts for the confounding effects and thus
removes spurious associations to a large extent. This is
particularly favorable when dealing with high throughput data
as it discovers only those direct interactions with high confidence.
The variables formed two major clusters. One cluster is
dominated by MRI-derived variables and the other by lipid
variables. As an exception, the section of the lipid cluster which is
associated with LMNA mutation as well as with DCM (as shown
in Table 2) was associated with EDThickness (LV, segment1)
(Figure 3B). This MR image parameter was increased in LMNA
mutation carriers and negatively correlated with most of the
molecular lipids found diminished in that group (Figure 3A).
We then investigated how the observed changes in lipids
associate with the anatomy of the heart. We reconstructed a mean
heart model and studied its sensitivity to specific lipid profiles.
Heart surface models were derived from the heart MR images for
the samples from Groups 1&2. The analysis was performed for
each surface point by regressing the lipid profiles to the heart
surface models’ deviations from the mean heart model. To
regularize the analysis, only the deviations on mean heart model’s
surface normal were studied. To illustrate the effect of a selected
lipid on the heart surface model, the mean value of the lipid was
Table 1. Summary of the study subjects included in the study. *P,0.1; **P,0.05.
Lamin+ Study Lamin2 Study
Group 1 2 3 4
Description LMNA mutation carriers Controls of Group 1 DCM-diagnosed subjects Controls of Group 3
Men/women 4/7 4/7 3/5 3/5
Age (years) 33,7 (11,9) 34,3 (10,2) 56,4 (11,3)** 35,8 (10,3)**
BMI (kg/m2) 23,9 (4,2) 24,5 (2,6) 28,3 (2,8)* 24,2 (4,9)*
Cardiac symptoms
chest pain 0 0 0 0
dyspnoea 1 0 5 0
palpitation 2 0 1 0
Cardiac diagnosis 1 0 8 0
none 0 11 0 8
healthy mutation carrier 10 0 0 0
DCM 0 0 8 0
Atrial fibrillation 1 0 0 0
Hypercholesterolemia 0 1 1 0
Cardiac medication 1 1 8 0
ACEinhibitor/ATRblocker 0 0 8 0
Betablocker 1 0 8 0
Digoxin 0 0 1 0
Diuretic 0 0 6 0
Statin 0 1 1 0
Warfarin 1 0 1 0
LMNA mutations 11 not determined 0 not determined
Ser143Pro 8
Ala132Pro 2
T1085Xdel 1
doi:10.1371/journal.pone.0015744.t001
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computed for the Group 2, and the heart surface model
corresponding to the mean lipid value was generated from the
regression models of each surface point. Then, the lipid value was
either increased or decreased (two times the standard deviation in
Group 2) according to the change observed in Group 1, and the
resulting heart model was generated. The change in the heart
model was visually evaluated by computing the wall thickening
and/or wall motion from end-diastolic shape to end-systolic shape
and visualizing the results using color maps overlaid on the mean
heart model.
Figure 4 shows the sensitivity of the heart model to change in
TG(49:3) concentration, i.e. a lipid found diminished in LMNA
mutation carriers as well as in DCM (Table 2 and Figure 2).
Figure 4A shows the change in wall thickening. Blue color indicates
locations of reduced wall thickening as lipid concentration was
decreasedwhereas red indicates increasedwall thickening. Figure 4B
shows the corresponding results for wall motion. Decrease of lipid
concentration caused decrease in wall thickening and motion in
septum. Also, reduced wall motion in base was observed.
Discussion
In this preliminary study we revealed that LMNA carriers at risk
of DCM are characterized by a distinct serum lipidomic profile as
compared to apparently healthy controls. The association analysis
using dependency network and regression approaches also helped
us to obtain novel insights into how the affected lipids relate to
cardiac shape and volume changes and confirm their disease
specificity.
Diminishment of odd-chain triglyceride in LMNA carriers was
associated with increased end-diastolic wall thickness in left
ventricle (Figure 3B) but the meaning of this finding is unclear.
Asynchrony might cause increased values when measurements are
made gated by ECG. Projection of the lipid change onto the
surface normal of the mean heart model was accompanied with
the decrease in wall thickening and motion in septum. This is in
line with earlier observations which show that DCM caused by
LMNA mutations is characterized by diminishing left ventricular
contractility while simultaneously the left ventricular end diastolic
dimension may enlarge only modestly or does not fulfill formal
criteria of DCM at all [14]. Among the affected lipids, the
diminished odd-chain triglycerides are of particular interest as they
were also diminished in DCM independent of LMNA mutation
and thus could be considered as DCM risk marker candidates but
this warrants further studies. Odd-chain triglycerides have been
previously associated with mitochondrial fat oxidation disorders
and their dietary supplementation has led to promising results in
the treatment of chronic cardiomyopathy, rhabdomyolysis, and
muscle weakness [15].
Odd-chain fatty acids are not endogenously synthesized in the
body but are abundant in some diets such as milk. In fact C15:0
and C17:0 fatty acids have been considered as biomarkers of
dietary milk fat intake [16]. Given the experimental setting of our
study, the diet itself is an unlikely factor behind the observed
diminishment of odd-chain triglycerides in the DCM groups.
Instead, the altered absorption of lipids or formation of
triglycerides from fatty acids in enterocytes are more plausible
factors. The potential roles of intestinal lipid uptake and formation
in the context of DCM are so far unexplored and there is currently
no evidence that the common Finnish LMNA mutations associate
with the intestinal lipid metabolism.
In order to characterize the molecular and physiological
disturbances during the prodromal phases of the disease of
relatively low incidence in general population, large prospective
studies are needed with long term and frequent follow-up. This is
in practice rarely possible. An alternative strategy applied also in
this study is to identify subjects at high risk of disease, e.g. specific
risk mutation carriers, and follow them up during the asymptom-
atic phase. In such case, additional studies may be needed to
demonstrate the disease-specificity of early molecular or pheno-
typic changes. The potential shortcoming of such a strategy is that
in many cases the study sample is small due to rarity of mutations
in the general population, and dealing with relatively small sample
sizes is an inherent statistical challenge that needs to be carefully
addressed. The LMNA carriers in this study mainly carry the
Ser143Pro mutation which is typical for the Finnish population.
All the mutations which these patients carry are known to associate
with cardiomyopathy later in middle age. The limitation of our
study is the small sample size of LMNA mutation carriers.
However, for modeling purposes, all available mutation carriers
were recruited to obtain a relatively homogeneous group of
subjects at risk of developing DCM.
In conclusion, using a novel integrative approach by combining
serum lipidomics and MR imaging in LMNA mutation carriers at
Table 2. Summary of between-group lipid changes in the
two studies (Lamin+ and Lamin2).
Lamin Group P-value Fold 25% 50% 75%
PC(38:5e) + 1 0,0426 0,7 0,50 0,60 0,84
+ 2 0,82 0,85 0,96
2 3 0,0307 0,7 0,46 0,50 0,54
2 4 0,65 0,72 1,03
PS(38:2) + 1 0,0080 0,6 2,07 2,48 2,78
+ 2 2,88 4,38 5,05
2 3 0,0348 0,7 1,05 1,29 1,57
2 4 1,50 1,86 2,33
TG(49:2)/TG(49:1) + 1 0,0194 0,9 0,61 0,73 0,79
+ 2 0,83 0,86 0,92
2 3 0,0011 0,6 0,51 0,56 0,65
2 4 0,90 0,96 1,07
TG(49:3) + 1 0,0002 0,5 1,70 2,05 2,62
+ 2 3,49 4,08 4,34
2 3 0,0212 0,6 1,56 2,13 2,57
2 4 3,04 3,68 4,70
TG(50:10) + 1 0,0195 0,8 0,66 1,27 1,69
+ 2 1,53 1,69 2,11
2 3 0,0104 0,6 1,77 2,17 2,77
2 4 3,04 3,68 4,70
TG(50:2)/TG(50:1) + 1 0,0151 0,5 0,02 0,03 0,03
+ 2 0,04 0,06 0,10
2 3 0,0025 0,1 0,00 0,01 0,01
2 4 0,03 0,05 0,06
TG(54:3)/TG(54:2) + 1 0,0359 0,8 3,24 4,49 5,15
+ 2 4,33 5,87 6,52
2 3 0,0004 0,4 1,74 2,05 2,61
2 4 3,98 5,16 5,48
Each lipid was separately compared between Groups 1&2 and 3&4 using the
two-sided t-test. Reported fold change is the median of Group 1 or Group 3
divided by the median of Group 2 or Group 4, respectively. Also shown are the
25%, 50% and 75% quantiles.
doi:10.1371/journal.pone.0015744.t002
Lipidomics and Cardiac MRI in DCM
PLoS ONE | www.plosone.org 4 January 2011 | Volume 6 | Issue 1 | e15744
risk of DCM, we have shown that specific lipid abnormalities such
as diminished odd-chain triglycerides precede DCM. Our findings
should be considered preliminary and the possible role of odd-
chain triglycerides in the development or prevention of DCM
warrant further investigations. On a general level, our study also
provides a framework for linking serum derived molecular markers
not only with clinical endpoints, but also with the more subtle
intermediate phenotypes, as derived from medical imaging, of
potential pathophysiological relevance.
Materials and Methods
Study Participants
The LMNA mutations had initially been identified among DCM
patients who participated in the molecular genetics study of DCM
carried out in collaboration between the Helsinki University
Hospital and the University of Kuopio [4,14]. Group one
comprised eleven mainly asymptomatic LMNA mutation carriers
from these families recruited between years 2004–2006. The
participants had not yet developed DCM by the time of this study
but it is known that the penetrance of LMNA mutations is high
[17]. None of these individuals had symptoms of skeletal muscle
disease. Cardiac MRI was performed and venous blood samples
obtained during years 2004–2006.
The second group consists of healthy controls matched to group
1: 11 individuals (four men and seven females) who did not have
any cardiac disease, recruited during year 2007. Clinical
examination, ECG and echocardiography (2-dimensional, M-
mode and Doppler) were performed to each of the participants to
exclude the possibility of cardiomyopathy or valvular disease.
Venous blood samples were drawn for lipid analyses. DNA
analyses were not performed.
Group three comprises eight unrelated DCM patients with no
LMNA mutation (three men and five women), who had been
diagnosed with DCM and followed up at the Department of
Cardiology of the Helsinki University Hospital. The diagnosis was
based on clinical examination, ECG and echocardiography.
Clinical data was obtained from the hospital records. Inclusion
criteria were LVEDD.27mm/m2 and EF,45% at time of
diagnosis. All patients who had secondary causes of DCM were
excluded. The subjects were asked to participate in the molecular
genetics study of DCM during the years 2000–2008. In some
patients the left ventricular function improved remarkably during
medication. In the gene analyses carried out either by SSCP (single
strand conformation polymorhism) -method or sequencing of the
LMNA gene at the University of Kuopio, no mutations in the
lamin A/C gene could be detected in these patients. Venous blood
samples were drawn for lipid and metabolomic analyses and
cardiac MRI studies were performed in year 2008.
Group four consists of healthy controls, matched for age and
sex with group three: eight previously healthy volunteers (three
men and five women), recruited in 2008. The possibility of
Figure 2. Logistic regression model using only one lipid variable, TG(49:3), moderately discriminates subjects at risk of DCM from
the controls. The model was trained using samples from Lamin+ study (LMNA mutation carriers and their controls) and applied to samples from
Lamin2 (DCM patients without LMNA mutation and their controls). (A) Parameter estimates, their standard errors and the z- and p-values of the
estimates of the logistic regression model. Negative parameter estimate indicates that the risk of DCM increases with lowering concentrations of
TG(49:3). (B) Model performance and (C) and ROC curves in Lamin+ and Lamin2 studies. Lower levels of TG(49:3) do not depend on the lamin
mutation (panel D) but are DCM specific (panel E).
doi:10.1371/journal.pone.0015744.g002
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Figure 3. Associations between the lipid profiles and the MR image parameters. (A) Heatmap of Pearson’s correlations between the lipid
profiles and the MR image parameters. (B) Partial correlation graph. An edge denotes partial correlation between the nodes it connects. Width of an
edge is proportional to the inverse of the non-rejection rate [13], which indicates the confidence with which the hypothesis of null partial correlation
is not rejected, that is, the chance of the edge not existing in the graph is the smaller the smaller the non-rejection rate is. A threshold of 0.53 was
used for the non-rejection rate: edges with higher values were omitted from the graph.
doi:10.1371/journal.pone.0015744.g003
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cardiomyopathy or valvular disease was excluded by clinical
examination, ECG and echocardiography (2-dimensional, M-
mode and Doppler). Venous blood samples were drawn for lipid
analyses. DNA analyses were not performed.
Informed consent was obtained from the study participants, and
the Ethics review Committee of the Department of Medicine,
University of Helsinki, approved this study.
MR Imaging
The imaging was done as described previously [9]. In short,
patients were evaluated by personal and family history, physical
examination, 12-lead ECG, and transthoracic echocardiography
(M-mode, two-dimensional and Doppler, Vivid 7, GE Medical).
The echocardiographic examinations were carried out by
experienced cardiologists. Cine MRI was performed with a 1.5
T system (Sonata, Siemens Medical Solution) and a body array
coil. A retrospectively ECG-gated segmented Steady State Free
Precession imaging was used with following parameters: echo time
1.6 ms, repetition time 3.0 ms, matrix 2566256, field of view
2406340 mm, flip angle 52 degree. Short-axis cine stack and a
long-axis cine slice of both ventricles were obtained with a section
thickness 6 mm, intersection gap 20%, and temporal resolution
42–49 ms.
Image Analysis
The left and right ventricles and epicardium were semi-
automatically segmented by a technician together with a
radiologist from each time frame of the cine MRI series with a
software tool developed for this purpose [18]. The automatic
segmentation took 1–2 minutes. To reach the optimal segmen-
tation accuracy the time used for the manual refinement was not
limited. In the tool, an a priori heart model, consisting of
triangulated surfaces of the ventricles and epicardium, was
deformed to fit both short- and long-axis MRI data. Because
the same a priori model was used for each subject, the number of
the surface points was identical in each case (906 points for left
ventricle, 1516 for right ventricle, and 906 for epicardium), and
the point-correspondence existed between all the subjects and
time frames. The surfaces were rigidly aligned in the same
coordinate system to remove the position and orientation
variations from the data. This enabled point-wise comparison
of the cardiac motion in the study population. The heart surface
models were also used to derive 86 MRI parameters that describe
anatomical and physiological features of the heart, as described
earlier [9].
Lipidomics
The lipidome was analyzed as described previously [19]. In
brief, serum samples (10 ml) diluted with 0.15 M NaCl (10 ml) and
spiked with a standard mixture containing 10 lipid species were
extracted with a mixture of chloroform and methanol 2:1 (100 ml).
The extraction time was 0.5 h and the lower organic phase was
separated by centrifuging at 10 000 r.p.m. for 3 min. Another
standard mixture containing three labeled lipid species was added
to the extracts and the lipids were analyzed on a Waters Q-Tof
Premier mass spectrometer combined with an Acquity Ultra
Performance LCTM (UPLC). The column, kept at 50uC, was an
Acquity UPLCTM BEH C18 1650 mm with 1.7 mm particles.
The solvent system included water (1% 1 M ammonium acetate,
0.1% HCOOH) and a mixture of acetonitrile and 2-propanol
(5:2, 1% 1 M NH4Ac, 0.1% HCOOH). The flow rate was
0.2 ml/min and the total run time including column re-
Figure 4. The effect of TG(49:3) on the wall thickening and wall motion of left ventricle. The difference in wall thickening in mm (Panel A)
and wall motion in mm (Panel B) between the mean lipid value of Group 2 and the decreased lipid value. The blue color indicates the regions where
the wall thickening/motion decreased when the TG(49:3) value was decreased. Therefore, the decreased function in these regions is associated with
the LMNA-related TG(49:3) concentration change. Respectively, red color indicates the regions that showed increased wall thickening/motion related
to the TG(49:3) concentration decrease in LMNA mutation.
doi:10.1371/journal.pone.0015744.g004
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equilibration was 18 min. Data were processed using MZmine
software version 0.6 [20,21]. Lipids were identified using the
internal spectral library.
Calibration was performed as follows: all monoacyl lipids except
cholesterol esters, such as monoacylglycerols and monoacyl-
glycerophospholipids, were calibrated with lysophosphatidylcho-
line PC(17:0/0:0) (Avanti Polar Lipids, Alabaster, AL) as an
internal standard. All diacyl lipids except phosphatidylethanol-
amines were calibrated with phosphatidylcholine PC(17:0/17:0)
(Avanti Polar Lipids), the phosphatidylethanolamines with
PE(17:0/17:0) (Avanti Polar Lipids) and the triglycerides and
cholesterol esters with triglyceride TG(17:0/17:0/17:0) (Larodan
Fine Chemicals, Malmo¨, Sweden).
Statistical analyses of variable dependencies
We calculated the marginal correlations the Pearson correla-
tions, which indicate the degree of linear dependency between a
pair of variables. The partial correlations were calculated as the
Pearson correlations, with the effect of a set of control variables
removed. In case the set of control variables includes all other
variables the partial correlation is ‘‘full’’ and it depicts the linear
dependency between the pair of variables that cannot be
explained by any linear combination of the other variables. In
‘‘omics’’ applications where the number of variables is usually
much larger than the number of samples, like in our case here, it
is not feasible to calculate the full partial correlations, but
efficient algorithms have been developed to estimate them with
restricted, q-order, partial correlations in which a set of q
variables are controlled [13]. In the network presentation we
used here, the width of a link is proportional to the inverse of the
non-rejection rate, which indicates the confidence with which
the hypothesis of null partial correlation is not rejected, that is,
the chance of the edge not existing in the graph is the smaller the
smaller the non-rejection rate is. All calculations were done in R
using the package qpgraph and networks were visualized using
Cytoscape (www.cytoscape.org) and yEd (www.yworks.com)
graphical editors.
Regression of lipid profiles on MRI parameters
In addition to correlation based analysis, regression methods
were applied to elucidate dependencies between the MR image
parameters and the lipid profiles in more detail. Due to the large
number of variables compared to sample size the regression must
be regularized and we chose to apply the elasticnet regression
method [22] as implemented in the elasticnet package of R.
Elasticnet is convenient for our current application because the L1
and L2 penalties on the regression coefficients can be flexibly tuned
by changing u1 and u2 respectively in Equation (1), which allows
exploration of solutions ranging from simple models with no lipids
at all to more complex ones that are either sparse, containing non-
correlated lipids, or non-sparse with several correlated lipids
included. Elasticnet solution is obtained by minimizing
L(u1,u2,b)~jjy{Xbjj2zu1jjbjj21zu2jjbjj22, ð1Þ
where u1 and u2 are tuning parameters, y is the response variable
and X a matrix containing the explanatory variables. In this study,
each of the image parameters were separately explained by the
whole lipid profile data and the tuning parameters were selected
by minimizing the mean cross-validation error:
em~1=n
Xn
i~1
ei,
ei~e(p(i),u1,u2,y,X )~jjyp(i){X{p(i)b{p(i)jj22, i~1,:::,n: ð2Þ
Above p = (p(1), …., p(n)) is partition of the samples into n blocks
and 2p(i) refers to all samples but those that belong to the i-th
block (which belong to p(i)). Here we randomly assigned the
samples into n = 5 blocks for 100 times and calculated the average
errors.
The cross-validation errors were also used to assess whether the
lipid profiles in general explained an image parameter. The
criterion was defined as follows:
eminzsd(ei,min)vecons ð3Þ
R The image parameter in question can be explained with the
lipid profiles.
Above emin is the minimum average cross-validation error, ei,min
is the standard deviation of the cross-validation errors over the n
blocks for the model that gives the minimum average error and
econs is the average cross-validation error of the constant model. In
other words, if the minimum mean cross-validation error plus one
standard deviation of the error at minimum was lower than the
mean cross-validation error of the constant model, i.e., a model
that contained no lipids, then the image parameter was interpreted
to be dependent on the lipid profiles. The final model for each
image parameter was estimated using all samples and the pair of
tuning parameters that corresponded to the minimum average
cross validation error.
Association of lipid values and heart shape
A mean heart surface model, S, was computed from the heart
surface models of Group 2. The heart model consisted both end-
diastole and end-systole phases. In addition, normal vectors ~ni
were computed for each surface point i of the mean heart model.
For each sample subject in Groups 1&2, the heart surface
model’s deviation from the mean heart model along the surface
normal was computed:
di,j~(~xi,j{~si):~n
T
i , ð4Þ
where~xi,j is the coordinates of i-th surface points of sample subject
j and~si the coordinates of mean heart surface model.
A linear regression model was computed for the values of a lipid
and the shape parameters di,j for each surface point:
di~aizbi:l, ð5Þ
where ai and bi are regression weights solved from the sample
subject data. The mean lipid value was computed for Group 2,
lGroup2, and the new shape parameters, di,Group2, were computed
from Equation 5 for the mean lipid value. The heart shape model
corresponding to the mean lipid value of Group 2 was obtained from
~xi,Group2~~sizdi,Group2~ni: ð6Þ
Then, the mean lipid value was changed by two standard deviations
according to the difference observed between Groups 1 and 2. The
heart surface model corresponding to the new lipid concentration
was computed as described above for the mean lipid value.
From the surface models observed, wall thickness along the
surface normal was determined for each surface point of left
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ventricle for end-diastole and end-systole, and their difference was
used as the wall thickening measure. Amount of wall motion along
surface normal was computed from the location of a surface point
in end-diastole and end-systole.
Supporting Information
Table S1 Comparisons of mean values of lipid variables in Group
1 vs. Group 2, and Group 3 vs. Group 4, respectively (two-sided t-
test). Reported fold change is the median of Group 1 or Group 3
divided by the median of Group 2 or Group 4, respectively.
(PDF)
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